For U.S. Healthcare Professionals
With RAVICTI, your patients with urea cycle disorders (UCDs)a can
LIVE CONFIDENTLY1
A single moment could change everything.
Give them RAVICTI. Their future is in your hands.
aThe safety and efficacy of RAVICTI for the treatment of N- acetylglutamate synthase (NAGS) deficiency have not been established.1
Elevated ammonia and glutamine levels can lead to serious outcomes.
See the subtle signs and symptoms to know for diagnosis.
See step-by-step instructions for the oral administration of RAVICTI
Watch the RAVICTI Oral Dosing Administration videoWatch the RAVICTI Oral Dosing Administration videoImportant information you need to start or switch your patients to RAVICTI
Use this test to determine your patient’s plasma PAA-PAGN ratio and urinary PAGN level
Find dosages for phenylbutyrate-naïve patients and patients currently taking NaPBA
References: 1. RAVICTI (glycerol phenylbutyrate) Oral Liquid [prescribing information] Horizon.
RAVICTI is indicated for the chronic management of patients with UCDs who cannot be managed by diet and supplementation alone. It must be used with dietary protein restriction. RAVICTI is not indicated for the treatment of acute hyperammonemia or for NAGS deficiency.1
RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).
The most common adverse reactions reported in clinical trials (at least 10% of patients) were:
Please see Full Prescribing Information.
RAVICTI is indicated for the chronic management of patients with UCDs who cannot be managed by diet and supplementation alone. It must be used with dietary protein restriction. RAVICTI is not indicated for the treatment of acute hyperammonemia or for NAGS deficiency.1
RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).
The most common adverse reactions reported in clinical trials (at least 10% of patients) were:
Please see Full Prescribing Information.